Connor Clark & Lunn Investment Management Ltd. Sells 20,792 Shares of Replimune Group, Inc. (NASDAQ:REPL)

Connor Clark & Lunn Investment Management Ltd. lessened its position in Replimune Group, Inc. (NASDAQ:REPL) by 16.2% in the 4th quarter, Holdings Channel.com reports. The fund owned 107,416 shares of the company’s stock after selling 20,792 shares during the period. Connor Clark & Lunn Investment Management Ltd.’s holdings in Replimune Group were worth $1,301,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. Baker BROS. Advisors LP lifted its stake in Replimune Group by 10.0% in the third quarter. Baker BROS. Advisors LP now owns 11,045,336 shares of the company’s stock worth $121,057,000 after purchasing an additional 1,000,000 shares during the last quarter. Braidwell LP lifted its stake in shares of Replimune Group by 203.0% during the 3rd quarter. Braidwell LP now owns 3,070,837 shares of the company’s stock worth $33,656,000 after acquiring an additional 2,057,460 shares during the last quarter. State Street Corp boosted its holdings in Replimune Group by 102.1% during the 3rd quarter. State Street Corp now owns 2,340,042 shares of the company’s stock valued at $25,647,000 after acquiring an additional 1,182,181 shares during the period. Geode Capital Management LLC grew its position in Replimune Group by 17.9% in the 3rd quarter. Geode Capital Management LLC now owns 1,428,301 shares of the company’s stock valued at $15,657,000 after acquiring an additional 217,308 shares during the last quarter. Finally, Parkman Healthcare Partners LLC increased its stake in Replimune Group by 45.5% in the third quarter. Parkman Healthcare Partners LLC now owns 763,747 shares of the company’s stock worth $8,371,000 after purchasing an additional 238,747 shares during the period. 92.53% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. JPMorgan Chase & Co. boosted their target price on shares of Replimune Group from $16.00 to $18.00 and gave the company an “overweight” rating in a research note on Wednesday, February 26th. HC Wainwright lifted their price target on shares of Replimune Group from $21.00 to $22.00 and gave the company a “buy” rating in a research note on Thursday, February 13th. BMO Capital Markets increased their price objective on Replimune Group from $18.00 to $27.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 22nd. Finally, Jefferies Financial Group lifted their target price on Replimune Group from $16.00 to $19.00 and gave the company a “buy” rating in a research report on Wednesday, December 4th. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Replimune Group currently has an average rating of “Buy” and a consensus target price of $19.43.

Replimune Group Trading Up 0.6 %

Shares of NASDAQ REPL opened at $11.50 on Thursday. Replimune Group, Inc. has a 1-year low of $4.92 and a 1-year high of $17.00. The business has a fifty day moving average price of $12.66 and a 200 day moving average price of $12.13. The stock has a market capitalization of $885.67 million, a P/E ratio of -3.75 and a beta of 1.30. The company has a debt-to-equity ratio of 0.14, a current ratio of 11.43 and a quick ratio of 11.43.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings results on Wednesday, February 12th. The company reported ($0.79) EPS for the quarter, missing the consensus estimate of ($0.70) by ($0.09). Equities research analysts expect that Replimune Group, Inc. will post -2.97 EPS for the current fiscal year.

Replimune Group Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.